# MicroRNAs in Long COVID: Key Regulators, Biomarkers, and Therapeutic Targets of Post-SARS-CoV-2 Sequelae

**Authors:** Rawan Makki, Sondos Kassem-Moussa, Fatima Al Nemer, Rania El Majzoub, Hussein Fayyad-Kazan, Walid Rachidi, Bassam Badran, Mohammad Fayyad-Kazan

PMC · DOI: 10.3390/biom16020283 · Biomolecules · 2026-02-11

## TL;DR

This paper explores how microRNAs may contribute to long COVID, offering insights into their role as biomarkers and potential therapies.

## Contribution

The paper provides a comprehensive review of miRNAs as regulators, biomarkers, and therapeutic targets in long COVID.

## Key findings

- Circulating miRNA signatures persist months after acute SARS-CoV-2 infection.
- miRNAs are linked to chronic immune activation and metabolic dysfunction in long COVID.
- miRNA-based interventions could offer precision-medicine strategies for long COVID.

## Abstract

COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), is clinically defined by persistent symptoms that endure beyond acute infection and affect multiple organ systems, including the immune, cardiopulmonary, neurological, and metabolic axes. The underlying mechanisms remain poorly resolved, limiting the development of targeted diagnostics and therapeutics. MicroRNAs (miRNAs), as key post-transcriptional regulators of gene expression, control inflammatory networks, antiviral responses, mitochondrial bioenergetics, and fibrotic pathways, all of which are implicated in long COVID pathogenesis. Recent studies show durable changes in circulating miRNA signatures months after recovery from the acute phase, suggesting a role in maintaining chronic immune activation and metabolic dysfunction. Importantly, circulating miRNAs are stable, quantifiable in biofluids, and reflect systems-level dysregulation, positioning them as promising biomarker candidates for patient stratification, symptom clustering, and disease monitoring. Moreover, miRNA-directed interventions, such as mimics and antagomiRs, represent an emerging precision-medicine strategy to correct sustained molecular disturbances. This review summarizes current evidence linking miRNAs to long COVID, highlights their biomarker potential, and discusses therapeutic avenues that may help advance mechanism-based interventions for this globally emerging chronic condition.

## Full-text entities

- **Genes:** MIR31 (microRNA 31) [NCBI Gene 407035] {aka MIRN31, hsa-mir-31, miR-31}, ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, DROSHA (drosha ribonuclease III) [NCBI Gene 29102] {aka ETOHI2, HSA242976, RANSE3L, RN3, RNASE3L, RNASEN}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, MIR1263 (microRNA 1263) [NCBI Gene 100302148] {aka MIRN1263, hsa-mir-1263}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, PIK3R2 (phosphoinositide-3-kinase regulatory subunit 2) [NCBI Gene 5296] {aka MPPH, MPPH1, P85B, p85, p85-BETA, p85beta}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, Mir146 (microRNA 146) [NCBI Gene 387164] {aka Mirn146, miR-146a, mmu-mir-146}, MIR210 (microRNA 210) [NCBI Gene 406992] {aka MIRN210, mir-210}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, DGCR8 (DGCR8 microprocessor complex subunit) [NCBI Gene 54487] {aka C22orf12, DGCRK6, Gy1, pasha}, MIR181C (microRNA 181c) [NCBI Gene 406957] {aka MIRN181C, mir-181c}, MIR155 (microRNA 155) [NCBI Gene 406947] {aka MIRN155, miRNA155, mir-155}, TARBP2P1 (TARBP2 pseudogene 1) [NCBI Gene 6896] {aka TARBP2P, TRBP}, Traf6 (TNF receptor-associated factor 6) [NCBI Gene 22034] {aka 2310003F17Rik, C630032O20Rik}, S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}, AGO4 (argonaute RISC component 4) [NCBI Gene 192670] {aka EIF2C4}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, RAN (RAN, member RAS oncogene family) [NCBI Gene 5901] {aka ARA24, Gsp1, TC4}, MIR23B (microRNA 23b) [NCBI Gene 407011] {aka MIRN23B, hsa-mir-23b, miRNA23B, mir-23b}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, DICER1 (dicer 1, ribonuclease III) [NCBI Gene 23405] {aka DCR1, Dicer, Dicer1e, GLOW, HERNA, K12H4.8-LIKE}, SDHB (succinate dehydrogenase complex iron sulfur subunit B) [NCBI Gene 6390] {aka CWS2, IP, MC2DN4, PGL4, PPGL4, SDH}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, SOCS1 (suppressor of cytokine signaling 1) [NCBI Gene 8651] {aka AISIMD, CIS1, CISH1, JAB, SOCS-1, SSI-1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, CEBPA (CCAAT enhancer binding protein alpha) [NCBI Gene 1050] {aka C/EBP-alpha, CEBP}, ZEB1 (zinc finger E-box binding homeobox 1) [NCBI Gene 6935] {aka AREB6, BZP, DELTAEF1, FECD6, NIL2A, PPCD3}, AGO2 (argonaute RISC catalytic component 2) [NCBI Gene 27161] {aka CASC7, EIF2C2, LESKRES, LINC00980, PPD, Q10}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, FBN1 (fibrillin 1) [NCBI Gene 2200] {aka ACMICD, ECTOL1, FBN, GPHYSD2, MASS, MFLS}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, Irak1 (interleukin-1 receptor-associated kinase 1) [NCBI Gene 16179] {aka IRAK, IRAK-1, IRAK1-S, IRAK1b, Il1rak, Plpk}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, SDHD (succinate dehydrogenase complex subunit D) [NCBI Gene 6392] {aka CBT1, CII-4, CWS3, MC2DN3, PGL, PGL1}, PDP1 (pyruvate dehydrogenase phosphatase catalytic subunit 1) [NCBI Gene 54704] {aka PDH, PDP, PDPC, PDPC 1, PPM2A, PPM2C}, NPM1 (nucleophosmin 1) [NCBI Gene 4869] {aka B23, NPM}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, KPNA3 (karyopherin subunit alpha 3) [NCBI Gene 3839] {aka IPOA4, SPG88, SRP1, SRP1gamma, SRP4, hSRP1}, MIR146A (microRNA 146a) [NCBI Gene 406938] {aka MIRN146, MIRN146A, miR-146a, miRNA146A}, SPRED1 (sprouty related EVH1 domain containing 1) [NCBI Gene 161742] {aka LGSS, NFLS, PPP1R147, hSpred1, spred-1}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, MIR126 (microRNA 126) [NCBI Gene 406913] {aka MIRN126, miRNA126, mir-126}, SMAD7 (SMAD family member 7) [NCBI Gene 4092] {aka CRCS3, MADH7, MADH8}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, MIR378A (microRNA 378a) [NCBI Gene 494327] {aka MIR378, MIRN378, hsa-mir-378, hsa-mir-378a, miRNA378}, TRAF6 (TNF receptor associated factor 6) [NCBI Gene 7189] {aka MGC:3310, RNF85}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MIR150 (microRNA 150) [NCBI Gene 406942] {aka MIRN150, miRNA150, mir-150}, ISCU (iron-sulfur cluster assembly enzyme) [NCBI Gene 23479] {aka 2310020H20Rik, HML, ISU2, NIFU, NIFUN, hnifU}, COX1 (cytochrome c oxidase subunit I) [NCBI Gene 4512] {aka COI, MTCO1}, DAPK2 (death associated protein kinase 2) [NCBI Gene 23604] {aka DRP-1, DRP1}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}
- **Diseases:** altered motility (MESH:C563515), hypoxia (MESH:D000860), autonomic dysfunction (MESH:D001342), pulmonary embolism (MESH:D011655), post-acute (MESH:D013313), autonomic dysregulation (MESH:D021081), neurological deficits (MESH:D009461), metabolic (MESH:D008659), ME/CFS (MESH:D015673), pulmonary and multiorgan dysfunction (MESH:D011660), stroke (MESH:D020521), pulmonary and systemic inflammation (MESH:D011014), Fatigue (MESH:D005221), function (MESH:D003291), myocardial damage (MESH:D009202), arrhythmias (MESH:D001145), organ injury (MESH:D009102), bleeding (MESH:D006470), hypoxic (MESH:D002534), dysautonomia (MESH:D054969), respiratory (MESH:D012131), asthma (MESH:D001249), neuroinflammation (MESH:D000090862), lung injury (MESH:D055370), acute lung injury (MESH:D055371), abdominal pain (MESH:D015746), diabetes (MESH:D003920), Endothelial dysfunction (MESH:D014652), fibrotic lung diseases (MESH:D008171), mitochondrial insufficiency (MESH:D000309), cancer (MESH:D009369), metabolic failure (MESH:D051437), dyspnea (MESH:D004417), Mitochondrial and Metabolic Dysfunction (MESH:D028361), syndromes (MESH:D013577), autoimmune encephalitis (MESH:D020274), Fibrosis (MESH:D005355), Metabolic disturbances (MESH:D024821), injury (MESH:D014947), neurodegeneration (MESH:D019636), disease (MESH:D004194), systemic infections (MESH:D012141), gut inflammation (MESH:D007249), sepsis (MESH:D018805), long COVID-related vascular disease (MESH:D000094024), chronic (MESH:D002908), cognitive (MESH:D003072), tissue injury (MESH:D017695), endothelial and (MESH:D005642), brain fog (MESH:D005222), post-exertional malaise (MESH:D000092202), Immune dysregulation (OMIM:614878), pulmonary fibrosis (MESH:D011658), hypersensitivity (MESH:D004342), Cardiac complications (MESH:D006331), fibrotic remodeling (MESH:D020257), heart failure (MESH:D006333), depressive disorders (MESH:D003866), inflammatory cytokines (MESH:D000080424), neuronal damage (MESH:D009410)
- **Chemicals:** nitric oxide (MESH:D009569), mannose (MESH:D008358), ROS (MESH:D017382), LPS (MESH:D008070), Lipid (MESH:D008055), ATP (MESH:D000255), MRG-229 (-)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], human gammaherpesvirus 4 (Epstein Barr virus, no rank) [taxon 10376]
- **Cell lines:** THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938461/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938461/full.md

## References

141 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938461/full.md

---
Source: https://tomesphere.com/paper/PMC12938461